Abstract
• PURPOSE: To evaluate the effect of treatment on the incidence of vision impairment and structural ocular complications among patients with Vogt-Koyanagi-Harada (VKH) disease. • DESIGN: Retrospective cohort study. • METHODS: setting: Single-center academic practice. study population: Twenty-four consecutive patients with VKH disease who were referred for evaluation and treatment from November 1984 through May 2004. procedures: Information on patients with VKH disease was entered retrospectively into a database and analyzed with time-dependent techniques. main outcome measures: Incidence of visual impairment and of structural ocular complications. • RESULTS: In better-seeing eyes, the frequencies of vision loss to 20/50 or worse and to 20/200 or worse at presentation were 50% and 30%, respectively. The incidence rates on follow-up examination for vision loss to 20/50 or worse and to 20/200 or worse were 9% per person-year and 7% per person-year in the better-seeing eye. Oral corticosteroid therapy was associated with a reduced risk of loss of visual acuity to the 20/200 or worse in the better-seeing eye (relative risk [RR] = 0.33; P = .05). The use of immunosuppressive drug therapy was associated with a reduced risk of vision loss to the 20/50 or worse and to the 20/200 or worse thresholds in the better-seeing eye (RR = 0.33; P = .05; and RR = 0.08; P = .04, respectively). • CONCLUSION: VKH disease may result in substantial visual impairment. The use of oral corticosteroid or immunosuppressive drug therapy may reduce the risk of vision loss during the follow-up period.
| Original language | English (US) |
|---|---|
| Journal | American Journal of Ophthalmology |
| Volume | 140 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2005 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
Vogt-Koyanagi-Harada disease : Clinical outcomes. / Bykhovskaya, Irina; Thorne, Jennifer; Kempen, John H.; Dunn, James P.; Jabs, Douglas.
In: American Journal of Ophthalmology, Vol. 140, No. 4, 10.2005.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vogt-Koyanagi-Harada disease
T2 - Clinical outcomes
AU - Bykhovskaya, Irina
AU - Thorne, Jennifer
AU - Kempen, John H.
AU - Dunn, James P.
AU - Jabs, Douglas
PY - 2005/10
Y1 - 2005/10
N2 - • PURPOSE: To evaluate the effect of treatment on the incidence of vision impairment and structural ocular complications among patients with Vogt-Koyanagi-Harada (VKH) disease. • DESIGN: Retrospective cohort study. • METHODS: setting: Single-center academic practice. study population: Twenty-four consecutive patients with VKH disease who were referred for evaluation and treatment from November 1984 through May 2004. procedures: Information on patients with VKH disease was entered retrospectively into a database and analyzed with time-dependent techniques. main outcome measures: Incidence of visual impairment and of structural ocular complications. • RESULTS: In better-seeing eyes, the frequencies of vision loss to 20/50 or worse and to 20/200 or worse at presentation were 50% and 30%, respectively. The incidence rates on follow-up examination for vision loss to 20/50 or worse and to 20/200 or worse were 9% per person-year and 7% per person-year in the better-seeing eye. Oral corticosteroid therapy was associated with a reduced risk of loss of visual acuity to the 20/200 or worse in the better-seeing eye (relative risk [RR] = 0.33; P = .05). The use of immunosuppressive drug therapy was associated with a reduced risk of vision loss to the 20/50 or worse and to the 20/200 or worse thresholds in the better-seeing eye (RR = 0.33; P = .05; and RR = 0.08; P = .04, respectively). • CONCLUSION: VKH disease may result in substantial visual impairment. The use of oral corticosteroid or immunosuppressive drug therapy may reduce the risk of vision loss during the follow-up period.
AB - • PURPOSE: To evaluate the effect of treatment on the incidence of vision impairment and structural ocular complications among patients with Vogt-Koyanagi-Harada (VKH) disease. • DESIGN: Retrospective cohort study. • METHODS: setting: Single-center academic practice. study population: Twenty-four consecutive patients with VKH disease who were referred for evaluation and treatment from November 1984 through May 2004. procedures: Information on patients with VKH disease was entered retrospectively into a database and analyzed with time-dependent techniques. main outcome measures: Incidence of visual impairment and of structural ocular complications. • RESULTS: In better-seeing eyes, the frequencies of vision loss to 20/50 or worse and to 20/200 or worse at presentation were 50% and 30%, respectively. The incidence rates on follow-up examination for vision loss to 20/50 or worse and to 20/200 or worse were 9% per person-year and 7% per person-year in the better-seeing eye. Oral corticosteroid therapy was associated with a reduced risk of loss of visual acuity to the 20/200 or worse in the better-seeing eye (relative risk [RR] = 0.33; P = .05). The use of immunosuppressive drug therapy was associated with a reduced risk of vision loss to the 20/50 or worse and to the 20/200 or worse thresholds in the better-seeing eye (RR = 0.33; P = .05; and RR = 0.08; P = .04, respectively). • CONCLUSION: VKH disease may result in substantial visual impairment. The use of oral corticosteroid or immunosuppressive drug therapy may reduce the risk of vision loss during the follow-up period.
UR - http://www.scopus.com/inward/record.url?scp=26844466276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26844466276&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2005.04.052
DO - 10.1016/j.ajo.2005.04.052
M3 - Article
C2 - 16226518
AN - SCOPUS:26844466276
VL - 140
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 4
ER -